Triplex vaccine construct and vaccination regimen. (A) Vaccine characteristic: schematic representation of Triplex vaccine. Direct repeats have been previously described.³⁴  FL1 and FL2 are flanking (FL) DNA of deletions II and III. Plasmid mH5-pp65-pLW51 and mH5-IEfusion-pZWIIA structures and the modified H5 promoter have been detailed elsewhere.^13,34  TK, thymidine kinase gene of MVA.³⁴  Arrows show direction of transcription. (B) Vaccination regimen: 2 injections of Triplex vaccine were administered at each DL as indicated. Postvaccination follow-up days are shown on the bar. Letters pointed by the blue arrows detail laboratory and immune evaluations, clinical and AE assessment. In detail, a, urine pregnancy test (female subjects); b, metabolic and hematologic panels; c, physical examination; d, electrocardiogram and troponin test; e, AE monitoring; f, MVA vector persistence measurements; g, immunological assays; h, CMV serology; I, HIV, hepatitis B and C tests; l, HLA typing at A and B loci. For b, f, g, h, i, and l, drawing blood was required.